
News &
Media
-
Stockhead: Neurotech partners with University of Sydney to advance Rett syndrome program
View More: Stockhead: Neurotech partners with University of Sydney to advance Rett syndrome program -
Stockhead: Neurotech gets crucial ethics approval to start phase III autism trial
View More: Stockhead: Neurotech gets crucial ethics approval to start phase III autism trial -
Stockhead: Peer-reviewed PANS data strengthens the case for Neurotech’s NTI164
View More: Stockhead: Peer-reviewed PANS data strengthens the case for Neurotech’s NTI164 -
Stockhead: Neurotech hopes to ride the medical cannabis deregulation Trump Bump
View More: Stockhead: Neurotech hopes to ride the medical cannabis deregulation Trump Bump -
Stockhead: Neurotech raising $4 million to drive NTI164 development
View More: Stockhead: Neurotech raising $4 million to drive NTI164 development -
Who’s Who with NTI: Neurotech Ieads the way in paediatric neurology treatments
View More: Who’s Who with NTI: Neurotech Ieads the way in paediatric neurology treatments -
Neurotech Secures Rare Pediatric Disease Designation for NTI164 in Rett Syndrome
View More: Neurotech Secures Rare Pediatric Disease Designation for NTI164 in Rett Syndrome -
Neurotech scores US FDA rare disease win for NTI164 in Rett syndrome
View More: Neurotech scores US FDA rare disease win for NTI164 in Rett syndrome -
Long Shortz with Neurotech: Dual strategy positions NTI164 for autism and Rett markets
View More: Long Shortz with Neurotech: Dual strategy positions NTI164 for autism and Rett markets